Immune cell therapy shows promise for tough leukemia cases

NCT ID NCT05358808

First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 28 times

Summary

This study tested a treatment called TCB008 for people with acute myeloid leukemia (AML) that came back or didn't respond to standard therapy. TCB008 uses donor immune cells (gamma-delta T cells) grown in a lab to attack the cancer. The trial aimed to see if these cells could reduce leukemia levels in the bone marrow and improve response rates. It included 16 adults with AML or related conditions, but the study was stopped early.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Bristol and Weston NHS foundation trust

    Bristol, BS2 8ED, United Kingdom

  • Cardiff and Vale University LHB

    Cardiff, CF14 4HH, United Kingdom

  • Guys&St Thomas NHS foundation Trust

    London, SE1 7EH, United Kingdom

  • Kings College Hospital

    London, SE5 9RS, United Kingdom

  • Queen Elizabeth University Hospital

    Glasgow, G51 4TF, United Kingdom

  • Royal Marsden Hospital

    London, SW3 6JJ, United Kingdom

Conditions

Explore the condition pages connected to this study.